This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Anika Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Anika Therapeutics.
6 Stocks That Popped Last Week
by Sejuti Banerjea
Take a look at why these stocks soared last week.
Anika Therapeutics (ANIK) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 47.62% and 14.59%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Anika Therapeutics (ANIK) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 50.00% and 2.81%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Anika Therapeutics (ANIK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANIK or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ANIK vs. TECH: Which Stock Is the Better Value Option?
Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder
by Zacks Equity Research
Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.
Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead
by Zacks Equity Research
Agenus (AGEN) enters into a collaboration agreement with Gilead to develop and commercialize up to five I-O therapies.
ANIK vs. RGEN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ANIK vs. RGEN: Which Stock Is the Better Value Option?
5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
by Kinjel Shah
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.
Anika Therapeutics Enters Oversold Territory
by Zacks Equity Research
Anika Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump
by Zacks Equity Research
Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
New Strong Buy Stocks for December 10th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
ANIK vs. RGNX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ANIK vs. RGNX: Which Stock Is the Better Value Option?
New Strong Buy Stocks for October 29th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Anika Therapeutics (ANIK) Q3 Earnings Beat Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 55.88% and -1.19%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Anika Therapeutics (ANIK) in Q3 Earnings?
by Zacks Equity Research
Anika Therapeutics (ANIK) is scheduled to report third-quarter earnings on Oct 24.
Anika Therapeutics (ANIK) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx Reports Top-line Data From Gene Therapy Candidate
by Zacks Equity Research
Ultragenyx (RARE) reports encouraging top-line data from two cohorts of the study evaluating its adeno-associated virus ("AAV") gene therapy candidate -- DTX301.
AMAG In-Licenses Global Rights to Orphan Drug Candidate
by Zacks Equity Research
AMAG acquires global rights to develop/market DIF from Velo Bio to boost its maternal health portfolio. The candidate is under assessment for treating severe preeclampsia in pregnant women.
AVEO Pharmaceuticals (AVEO) Soars: Stock Adds 6.4% in Session
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) shares rose more than 6% in the last trading session, amid huge volumes.
Verastem Out-Licenses China Rights to Cancer Drug Copiktra
by Zacks Equity Research
Verastem (VSTM) out-licenses rights to develop/commercialize its newly approved cancer drug Copiktra to the Chinese entity, CSPC Pharmaceutical.
Novavax (NVAX) Catches Eye: Stock Jumps 7.6%
by Zacks Equity Research
Novavax (NVAX) shares rose nearly 8% in the last trading session, amid huge volumes.
Arena (ARNA) Posts Favorable Top-Line Data on Pain Candidate
by Zacks Equity Research
Arena (ARNA) releases initial optimistic outcomes from a phase IIa study on its pipeline candidate olorinab for treating abdominal pain associated with Crohn's disease.